指南与共识泌尿生殖与妇科肿瘤放疗放疗物理与技术

宫颈癌辅助放化疗后复发模式:3期临床试验PARCER对更新版NRG肿瘤学/RTOG靶区勾画指南的评估

Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2022-02-12

本研究基于3期随机对照试验(NCT01279135)纳入300例宫颈癌辅助放化疗患者,分析盆腔复发模式。19例盆腔复发中,9例落在旧版RTOG/PARCER勾画指南范围内,12例落在新版RTOG 2021勾画指南范围内,对应局部复发进一步降低1%(P=0.007)。新指南勾画使直肠剂量边缘性增加,其他危及器官剂量无差异。

要点

  • 300例宫颈癌辅助放化疗患者中,远处转移最常见(15%),盆腔复发率为8%。
  • 19例盆腔复发中,旧版RTOG/PARCER指南覆盖9例,新版RTOG 2021指南覆盖12例,对应局部复发进一步降低1%(P=0.007)。
  • 新指南勾画使直肠剂量边缘性增加,其他危及器官剂量无差异。

核心结论

  • 本研究支持在接受子宫切除术的宫颈癌患者中使用新发布的NRG/RTOG勾画指南。
  • 需要进一步数据来确定是否需要像PARCER试验那样将临床靶区向前延伸。

研究设计与样本

  • 本研究为3期随机对照试验(NCT01279135)的事后分析,纳入300例接受辅助放化疗的宫颈癌患者以分析复发模式。
  • 对盆腔复发患者,将复发时诊断图像上的肿瘤大体体积勾画后叠加至放疗治疗计划扫描,分类为落在旧版RTOG/PARCER靶区勾画指南范围内或新版NRG/RTOG指南范围内,并比较两种指南覆盖的复发比例。
  • 另对有限数量患者基于新指南生成调强放疗治疗计划,以观察新指南是否增加危及器官剂量。

主要发现

  • 最常见复发形式为远处转移(15%),本研究中盆腔复发率为8%。
  • 19例复发中,9例被旧版RTOG/PARCER试验勾画指南覆盖,12例被新版RTOG 2021勾画指南覆盖,对应局部复发进一步降低1%(P=0.007)。
  • 新勾画指南使直肠剂量边缘性增加,其他危及器官剂量无差异。
  • 60例复发患者中25例接受了挽救治疗。
  • 复发后接受局部治疗的患者复发后平均生存期为27.2个月,仅接受支持治疗者为8个月。

关键数值与推荐

  • 盆腔复发分类标准为「落在旧版RTOG/PARCER靶区勾画指南范围内」或「落在新版NRG/RTOG指南范围内」或两者兼有。
  • 统计学显著性定义为P值<.05。
  • 19例盆腔复发中,旧版RTOG/PARCER指南覆盖9例,新版RTOG 2021指南覆盖12例,对应局部复发进一步降低1%(P=0.007)。

临床怎么用

  • 本研究支持在接受子宫切除术的宫颈癌患者中使用新发布的NRG/RTOG勾画指南。
  • 作者指出需要进一步数据来确定是否需要像PARCER试验那样将临床靶区向前延伸。

局限性

  • 需要进一步数据来确定是否需要像PARCER试验那样将临床靶区向前延伸。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Radiation Therapy Oncology Group (RTOG) under NRG Oncology recently published updated contouring guidelines for intensity modulated radiation therapy in postoperative treatment for endometrial and cervical cancer. The present study was designed to evaluate the implications of newly published guidelines. METHODS AND MATERIALS: We recruited 300 patients in a phase 3 randomized controlled trial of adjuvant chemoradiation therapy for cervical cancer (NCT01279135) to understand patterns of relapse. For those patients with pelvic relapse, we imported radiation therapy structure sets, treatment plans, and diagnostic images at relapse on the treatment planning system. We performed rigid registration with treatment planning images that contained the delineated planning target volume and radiation dose information. We delineated gross tumor volume at time of relapse on the diagnostic scans and superimposed it on the radiation therapy treatment scans. We categorized the site of pelvic relapse as "within field of old RTOG/[Postoperative Adjuvant Radiation in Cervical Cancer (PARCER)] target delineation guidelines" or "within field of new NRG/RTOG guidelines," or both, and compared proportions of recurrences contained within the 2 guidelines. We consider a P value of <.05 statistically significant. Additionally, we generated intensity modulated radiation therapy treatment plans based on the new guidelines for a limited set of patients to see if these new guidelines increased the organ at risk doses. RESULTS: Most common form of relapse was distant metastasis (15%). Pelvic relapse rate in our study was 8%. Overall, 9 out of 19 relapses were encompassed in the contouring guidelines of the old RTOG/ Postoperative Adjuvant Radiation in Cervical Cancer (PARCER) trial, and 12 out of 19 were encompassed within the new RTOG 2021 contouring guidelines. This corresponded to a further 1% reduction in local relapses (P = .007). Dose to rectum was marginally increased with the new contouring, with no difference in other organs at risk. Salvage treatment was offered in 25 out of 60 patients who relapsed. Patients who received local treatment after relapse had a mean survival after relapse of 27.2 months compared with 8 months among those who received supportive care alone. CONCLUSIONS: Our study supports the use of newly published NRG/RTOG contouring guidelines in patients with cervical cancer who have undergone hysterectomy. Further data are needed to ascertain if anterior extension of the clinical target volume is needed as in the Postoperative Adjuvant Radiation in Cervical Cancer trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mittal P, Chopra S, Charnalia M, et al. Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines. Int J Radiat Oncol Biol Phys. 2022. PMID: 35157993. doi:10.1016/j.ijrobp.2022.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。